EGFR-IN-9

Cat. No.: HY-18213

CAS No.: 1226549-39-8

Molecular Formula: $C_{29}H_{24}N_4O_3$

Molecular Weight: 476.53

Target: EGFR

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (209.85 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0985 mL	10.4925 mL	20.9850 mL
	5 mM	0.4197 mL	2.0985 mL	4.1970 mL
	10 mM	0.2099 mL	1.0493 mL	2.0985 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC_{50}s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity[1].

IC_{50} & Target

EGFR (WT)	$EGFR^{L858R/T790M}$
7 nM (IC_{50})	28 nM (IC_{50})

In Vitro

EGFR-IN-9 (Compound 8) shows antiproliferative activity in HCC827 lung cancer cell line with an IC_{50} of 8 nM.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Coumar MS, et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor leadidentification. J Med Chem. 2010 Jul 8;53(13):4980-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA